Elnour Asim Ahmed, Ahmed Islam Mohammed, Khalid Al-Kubaissi, Elmustafa Mohamed
PhD, MSc. Program of Clinical Pharmacy, College of Pharmacy, Al Ain University (AAU), Abu Dhabi campus, Abu Dhabi-United Arab Emirates (UAE). AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates.
PhD student, MSc, B Pharm. Department of Pharmacology, Faculty of Pharmacy, University of Gezira, Wad Medani-Sudan. b. Faculty of Pharmacy, Managel University for Science and Technology, Managel-Sudan.
Pharm Pract (Granada). 2022 Jul-Sep;20(3):2722. doi: 10.18549/PharmPract.2022.3.2722. Epub 2022 Sep 14.
Warfarin is well known as a narrow therapeutic index that has prodigious variability in response which challenges dosing adjustment for the maintenance of therapeutic international normalized ratio. However, an appreciated population not on new oral anticoagulants may still need to be stabilized with warfarin dosing.
The current study's main objective was to validate and compare two models of warfarin clinical algorithm models namely the Gage and the International Warfarin Pharmacogenetics Consortium (IWPC) with warfarin 5 mg fixed standard dosing strategy in a sample of Sudanese subjects.
We have conducted a cross-sectional study recruited from the out-patient clinic at a tertiary specialized heart center. We included subjects with unchanged warfarin dose (stabilized), and with therapeutic international normalized ratio. The predicted doses of warfarin in the two models were calculated by three different methods (accuracy, clinical practicality, and the clinical safety of the clinical algorithms).
The primary outcomes were the measurements of the clinical (accuracy, practicality, and safety) in each of the two clinical algorithms models compared to warfarin 5 mg fixed standard dose strategy.
We have enrolled 71 Sudanese subjects with mean age (51.7 ± 14 years), of which (49, 69.0%) were females. There was no significant difference between the warfarin 5 mg fixed standard dose strategy and the predicted doses of the two clinical algorithm models (MAE 1.44, 1.45, and 1.49 mg/day [P =0.4]) respectively. In the clinical practicality, all of the three models had a high percent of subjects (95.0%, 51.9%, and 66.7%) in the ideal dose range in middle dose group (3-7 mg/ day) for warfarin 5 mg fixed standard dosing strategy, Gage, and IWPC clinical algorithm models respectively. However, a small percent of subjects was exhibited in the warfarin low dose group ≤ 3 mg/day (0.0%, 15.0%, and 10.0%) and warfarin high dose group ≥ 7 mg/day (0.0%, 33.3%, and 33.3%) for warfarin 5 mg fixed standard dosing strategy, Gage, and IWPC clinical algorithms respectively. In terms of clinical safety, the percent of subjects with severely over-prediction were 28.2%, 22.5%, and 22.5% for warfarin 5 mg fixed standard dosing, Gage, and IWPC, respectively. While the percent of severely under-prediction was 12.7%, 7.0%, and 5.6% for the warfarin 5 mg fixed standard dosing, Gage, and IWPC, respectively.
The Gage and IWPC clinical algorithm models were accurate, more clinically practical, and clinically safe than warfarin 5 mg standard dosing in the study population. The cardiologist can use either models (Gage and IWPC) to stratify subjects for accurate, practical, and clinically safe warfarin dosing..
华法林是一种治疗指数狭窄的药物,其反应具有很大的变异性,这给维持治疗性国际标准化比值的剂量调整带来了挑战。然而,一部分未使用新型口服抗凝剂的患者可能仍需要通过华法林剂量调整来实现稳定治疗。
本研究的主要目的是在苏丹受试者样本中,验证并比较两种华法林临床算法模型,即盖奇模型(Gage)和国际华法林药物基因组学联盟(IWPC)模型,与华法林5mg固定标准剂量策略。
我们进行了一项横断面研究,研究对象来自一家三级专业心脏中心的门诊。我们纳入了华法林剂量不变(稳定)且国际标准化比值处于治疗范围的受试者。通过三种不同方法(准确性、临床实用性和临床算法的临床安全性)计算两种模型中华法林的预测剂量。
主要结局是将两种临床算法模型中的每一种与华法林5mg固定标准剂量策略进行比较,评估其临床(准确性、实用性和安全性)指标。
我们招募了71名苏丹受试者,平均年龄为(51.7±14岁),其中49名(69.0%)为女性。华法林5mg固定标准剂量策略与两种临床算法模型的预测剂量之间无显著差异(平均绝对误差分别为1.44、1.45和1.49mg/天[P = 0.4])。在临床实用性方面,对于华法林5mg固定标准剂量策略、盖奇模型和IWPC临床算法模型,中剂量组(3 - 7mg/天)中处于理想剂量范围内的受试者百分比分别为95.0%、51.9%和66.7%。然而,在华法林低剂量组≤3mg/天中,三种模型对应的受试者百分比分别为0.0%、15.0%和10.0%;在华法林高剂量组≥7mg/天中,对应的受试者百分比分别为0.0%、33.3%和33.3%。在临床安全性方面,华法林5mg固定标准剂量、盖奇模型和IWPC模型中,预测严重过量的受试者百分比分别为28.2%、22.5%和22.5%。而预测严重不足的百分比分别为12.7%、7.0%和5.6%。
在研究人群中,盖奇模型和IWPC临床算法模型比华法林5mg标准剂量更准确、更具临床实用性且临床安全性更高。心脏病专家可以使用这两种模型(盖奇模型和IWPC模型)对受试者进行分层,以实现准确、实用且临床安全的华法林给药。